SLU-PP-332 New Zealand: What the Research Shows

The short answer

SLU-PP-332 is an investigational synthetic small molecule studied in preclinical laboratory and animal models. It is not a peptide, despite often being grouped with research peptides online. It is a pan-agonist of the estrogen-related receptors, a family of nuclear receptors involved in cellular energy metabolism.

There are no completed human clinical trials of SLU-PP-332. It is not approved by the Therapeutic Goods Administration, it does not appear on the New Zealand Register of Therapeutic Goods as a medicine, and it is not an approved supplement. Where it is supplied in New Zealand, including by Synergy Bio, it is intended for laboratory research use only and not for human or veterinary use.

What SLU-PP-332 actually is

SLU-PP-332 is a synthetic small-molecule compound first developed as a pharmacological research tool at Saint Louis University, associated with work from the Burris laboratory. It was designed to activate the estrogen-related receptors, often shortened to ERRs, which include three related forms known as ERR alpha, ERR beta and ERR gamma.

Published laboratory characterisation describes it as a pan-ERR agonist, meaning it activates all three forms, with the strongest reported activity at ERR alpha. In reporter-gene assays using cultured cells, researchers have measured potency values in the nanomolar range for each receptor form. These are cell-based and animal-based findings and do not describe effects in people.

Key points about its identity

• It is a small molecule, not a peptide, so reconstitution and peptide handling guides do not describe what it is.
• It was created as a tool to study ERR biology in the laboratory.
• Reported activity is strongest at ERR alpha, with weaker activity at ERR beta and ERR gamma.
• All published data to date comes from cell cultures and animal models.

How the mechanism is described in research

The estrogen-related receptors sit inside cells and help regulate genes linked to energy production and mitochondrial activity. Mitochondria are the structures that generate chemical energy within cells. Because ERRs influence these pathways, researchers have studied compounds that activate them as a way to explore how energy metabolism is controlled.

In published preclinical work, SLU-PP-332 has been investigated under the label of an exercise mimetic. That term describes a research idea, that a compound might switch on some of the same gene programs that physical activity activates in muscle tissue. This framing comes from cell and rodent studies and is a description of a research hypothesis, not a demonstrated outcome in humans.

What the preclinical studies looked at

Published studies to date have examined SLU-PP-332 in cultured muscle cells and in mice. These reports describe measurements such as changes in mitochondrial activity in cell lines and changes in metabolic and muscle-related markers in rodent models of metabolic syndrome. Separate preclinical work has also explored ERR agonists of this class in animal models of cardiac stress.

All of these findings sit at the preclinical stage. Results observed in cells or in mice frequently do not carry over to humans, and many research compounds that show activity in animals are never approved for any human use. The appropriate reading of this literature is that SLU-PP-332 is an active area of basic science inquiry, not an established intervention.

Because there is no human trial data, any description of what SLU-PP-332 might do in a person would be speculation. This guide does not make, and cannot responsibly make, any such statement.

New Zealand regulatory status

In New Zealand, therapeutic goods are regulated by the Therapeutic Goods Administration. A product generally needs to be entered on the New Zealand Register of Therapeutic Goods before it can be lawfully supplied for a therapeutic use. SLU-PP-332 has no such approval. It is not a registered medicine, it is not a listed supplement, and it has no recognised therapeutic use in New Zealand.

Because it has no approved therapeutic use, SLU-PP-332 is handled as a research chemical. When Synergy Bio supplies it, the intended use is laboratory research only. It is not supplied for human consumption, injection, dosing or any form of self-administration. This guide does not provide dosing information, protocols or administration instructions, because none of that would be appropriate for a research-use-only compound.

What research-use-only means in practice

• It is not a medicine and has not been assessed by the TGA for safety or efficacy in people.
• It is not intended for human or veterinary use.
• It should be handled only by appropriately equipped and trained laboratory personnel.
• Any individual wanting to understand their own legal position should seek qualified advice.

Anti-doping context

Compounds described as exercise mimetics and metabolic modulators are of interest to anti-doping organisations. The World Anti-Doping Agency maintains categories covering metabolic modulators, and 2026 analytical research has characterised SLU-PP-332 and related ERR agonists specifically in the context of developing detection methods, describing them as compounds with doping potential.

This is included here as neutral context only. Athletes and support staff who fall under anti-doping rules are responsible for understanding their own obligations and should consult their relevant sporting body or anti-doping authority. Nothing here is advice about competition or testing.

How to read online claims

SLU-PP-332 has attracted attention across supplement and research-chemical websites, and some of that coverage presents animal findings as if they applied to people. A conservative reading keeps three things separate, what has been shown in cells, what has been shown in animals, and what is known about humans, which at present is nothing from clinical trials.

Preclinical interest is a starting point for science, not a conclusion about human outcomes.

If you are evaluating information about SLU-PP-332, look for whether a claim is tied to a cell study, an animal study or a human trial, and treat any human performance or health claim with caution given the absence of clinical data.

Frequently asked questions